This week’s trip: the biggest DMT depression study yet, new research, and laws on the move.
How Dr. Dave Rabin’s pursuit of safety, empathy, and evidence is reshaping the way psychiatry understands recovery.
This week’s trip: Phase 3 momentum, one-dose depression signals, ancient mystery science, and relationship research as policy inches forward behind public behavior.
A joy-first mushroom retreat in Jamaica that treats laughter and play like real medicine, not a bonus.
This week’s trip: a national microdosing surge, new research signals, and policy pressure rising as public behavior moves faster than the system.
Ask.Psychedelics.com — Honest answers. Real sources. One search.
Inside the “everything and nothing” state: what 5-MeO-DMT does to experience, and what Imperial College London is finding in the brain.
Turkey tail, cordyceps, and the power of compliance rules.
A wild mushroom triggers “fairytale human” visions. It contains zero psilocybin.
A veteran-led nonprofit proves its psychedelic healing model works. The VA says it doesn’t even meet “threshold requirements.”
This week’s trip: new LSD data conflicts across trials, microdosing takes a complicated turn, and anecdotal reports keep the debate alive.
This week’s trip: ibogaine policy takes center stage, veterans drive the movement for change, and psilocybin meets the science of longevity.
